Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Gossamer Bio, Inc.NASDAQ: GOSS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $512K rose 1.6% year over year, behind the +176.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 87.1% from the prior quarter. Over 3 fiscal years it compounded at -62.0% a year.

Context

  • Financing cash flow amounted to 13.3% of revenue in FY2025, up 3.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +1.6% toward the trailing-twelve-month pace of +176.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$512K-87.1% QoQ
Last fiscal yearDec 2025
$6.43M+155.9% YoY
LTMMar 2026
$6.43M+176.3% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%——
1 year+155.9%——
3-year CAGR-62.0%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
6.43M USD
Year-over-year change
+155.9%
4-year CAGR
+17.9%

Financing Cash Flow vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 financing cash flow of $6.43M is the smallest of the 9 companies compared; the peer median is $74.88M.
  • Its year-over-year change of +176.3% is the 5th highest of 8, against a peer median of +360.2%.
  • Financing cash flow amounts to 11.6% of revenue for GOSS, versus a peer median of 39.2%.
GOSS Competitors Peer median
Financing Cash Flow for GOSS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$256.78M -1.3%+662.8%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$226.9M +360.2%——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$124.44M +575.7%+232.1%141.0%
RGNXREGENXBIO Inc.LTM Mar 2026$108.93M +421.9%—124.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$40.83M +2642.3%—58.6%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$22.93M ——19.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$10.8M +25.0%-54.9%3.6%
PRTAProthena Corporation plcLTM Mar 2026$7.03M -1150.0%—12.1%
GOSSGossamer Bio, Inc.LTM Mar 2026$6.43M +176.3%-62.0%11.6%
Peer median (excluding GOSS) $74.88M+360.2%+232.1%39.2%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
Deferred Income Tax00000
Stock-Based Compensation32.01M42.55M28.52M20.62M10.56M
Change in Working Capital774K(4.46M)(14.84M)39.46M(13.63M)
Accounts Receivables000(5.34M)(6.89M)
Inventory00000
Accounts Payables(4.43M)(1.81M)3.99M(1.66M)(2.75M)
Other Working Capital5.2M(2.65M)(18.83M)46.45M(3.99M)
Other Non-Cash Items7.17M(177K)2.6M(11.17M)1.18M
Operating Cash Flow(188.89M)(187.03M)(159.16M)(3.47M)(171.27M)
Capital Expenditures(1.62M)(475K)00(79K)
Acquisitions (Net)0(65K)000
Purchases of Investments(152.03M)(238.06M)(441.67M)(494.78M)(227.11M)
Sales of Investments36.23M237.5M330.7M523.8M383.54M
Other Investing Activities(75K)65K000
Investing Cash Flow(117.43M)(1.04M)(110.97M)29.02M156.36M
Debt Repayment0(5.81M)(11.61M)(12.58M)0
Common Stock Issued0119.95M201.32M464K6.43M
Common Stock Repurchased000629K0
Dividends Paid00000
Other Financing Activities3.33M2.95M444K00
Financing Cash Flow3.33M117.09M190.15M(11.49M)6.43M
Effect of Forex Changes(165K)(517K)110K(102K)141K
Net Change in Cash(303.15M)(71.49M)(79.86M)13.97M(8.34M)
Free Cash Flow(190.51M)(187.51M)(159.16M)(3.47M)(171.35M)

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.